^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the panel recommends chemotherapy corresponding to initial therapy for metastatic disease (eg, FOLFIRI, FOLFOX, or CAPEOX chemotherapy alone or with bevacizumab; FOLFIRI or FOLFOX with panitumumab or cetuximab; FOLFIRINOX alone or with bevacizumab)...Colon cancer: SUBSEQUENT THERAPY...Irinotecan + (cetuximab or panitumumab)...Systemic therapy...FOLFIRINOX ± panitumumab or cetuximab
Secondary therapy:
FOLFOX; FOLFIRINOX; irinotecan; FOLFIRI
